Tecentriq (atezolizumab) / Roche 
Welcome,         Profile    Billing    Logout  
 31 Diseases   517 Trials   517 Trials   19434 News 
701 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
2019-001679-36: Treatment Of Metastic Bladder cancer at the time Of biochemical reLApse following radical cystectomy Behandling af metastatisk blærekræft ved biokemisk recidiv efter radikal cystektomi

Not yet recruiting
4
282
Europe
Atezolizumab, L01XC32, Concentrate for solution for infusion, Tecentriq
Aarhus University, F. Hoffmann-La Roche Ltd.
Biochemical relapse in patients who have undergone radical cystectomy because of muscle-invasive transitional cell carcinoma of the urinary bladder Biokemisk recidiv hos patienter, der har fået foretaget cystektomi grundet urotelial carcinom i urinblæren, Patients with relapse detected with a blood sample, who previously have undergone removal of the urinary bladder due to muscle-invasive bladder cancer Patienter, der tidligere har fået foretaget kirurgisk fjernelse af urinblæren grundet blærekræft, som aktuelt har biokemisk tilbagefald målt i en blodprøve, Diseases [C] - Cancer [C04]
 
 
BUDDY, NCT04059887: Evaluation of Blood TMB for the Efficacy of Atezolizumab []

Completed
4
100
RoW
Atezolizumab Injection [Tecentriq], Tecentriq
Chonnam National University Hospital, Roche Pharma AG
Lung Neoplasm Malignant
12/21
06/22
ChiCTR2100042367: A single arm trial of the atezolizumab plus chemotherapy as neoadjuvant therapy for limited-stage small cell lung cancer patients

Recruiting
4
16
China
atezolizumab+carboplatin+etoposide
Beijing Chest Hospital, Capital Medical University ; Beijing Chest Hospital, Capital Medical University, Beijing Chest Hospital, Capital Medical University
limited-stage small cell lung cancer
 
 
MINUTE, NCT06031233: Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Recruiting
4
679
Europe
Nivolumab, Pembrolizumab, Ipilimumab, Durvalumab, Atezolizumab, Bevacizumab, Trastuzumab
Isala
Oncology, Infusion Reaction
07/24
12/24
NCT05717400: Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Recruiting
4
15
US
Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Atezolizumab, MPDL3280A, TECENTRIQ, Sofosbuvir, Velpatasvir, Voxilaprevir, Ribavirin
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Liver Cancer
10/24
10/26
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Not yet recruiting
4
600
NA
Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Unresectable Hepatocellular Carcinoma
09/25
01/27
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Recruiting
4
136
Europe
Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed
Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-Small Cell Lung Cancer Metastatic
10/25
10/26
NCT05185505: Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Recruiting
4
24
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin
The Methodist Hospital Research Institute, Genentech, Inc.
Hepatocellular Carcinoma, Hepatocellular Cancer
04/27
10/27
WJOG11218L, jRCT2080224500: A multicentre, open-label, randomized Phase III Study of Atezolizumab with Platinum-Pemetrexed with or without Bevacizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer ( Investigator-Initiated Clinical Trial)

Completed
3
400
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche, carboplatin - Generic mfg., pemetrexed - Generic mfg.
Kyushu University Hospital, Chugai Pharmaceutical Co., Ltd
Non-Small-Cell Lung Cancer;Oncology
 
 
BEAT-SC, jRCT2080224946: Tecentriq_SCLC(1L)_Bev_comb[]

Completed
3
330
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche
Chugai Pharmaceutical Co., Ltd.
Extensive-stage Small Cell Lung Cancer
 
 
jRCTs031210393: JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer

Recruiting
3
330
Japan
carboplatin - Generic mfg., etoposide oral - Generic mfg., cisplatin - Generic mfg., Tecentriq (atezolizumab) - Roche, Imfinzi (durvalumab) - AstraZeneca
Dokkyo Medical University Hospital, National Cancer Center Japan
Extensive stage small cell lung cancer
 
 
2017-005142-29: immunotherapie treatment with arradiation treatment for advanced Non-small cell lung cAncer Traitement immunothérapie couplé a un traitement irradiant dans le cancer du poumons avancé non à petites cellules

Not yet recruiting
3
510
Europe
Atezolizumab, Nivolumab, Pembrolizumab, Solution for infusion, Tecentriq, Opdivo, Keytruda
UNICANCER, Programme Hospitalier de Recherche Clinique
Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 or PD-L1 antagonist according to the European Marketing Authorisation in a first line or a second line Patients atteints d'un Cancer du poumon avancé a non petites cellules (stade IIIB / IIIC / IV) pouvant être traités avec un antagoniste PD-1 ou PD-L1 selon l'autorisation de mise sur le marché européenne en première ou en deuxième ligne, NON SMALL CELL LUNG CANCER Cancer du poumons avancé à non petites cellules, Diseases [C] - Cancer [C04]
 
 
2019-001146-17: STUDY OF ATEZOLIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER STUDIO DI FASE IIIB SU ATEZOLIZUMB (TECENTRIQ) IN ASSOCIAZIONE CON CARBOPLATINO PIÙ ETOPOSIDE PER VALUTARE LA SICUREZZA E L’EFFICACIA IN PAZIENTI AFFETTI DA CARCINOMA POLMONARE A PICCOLE CELLULE IN STADIO ESTESO

Not yet recruiting
3
150
Europe
Atezolizumab, Carboplatino, Etoposide, [RO5541267], [NA], Concentrate for solution for infusion, Tecentriq, Carboplatino AHCL, Etoposide
ROCHE SPA, Roche SpA
EXTENSIVE-STAGE SMALL CELL LUNG CANCER (es-SCLC) Carcinoma polmonare a piccole cellule-stadio esteso (es-SCLC), Small-cell lung cancer Tumore del polmone a piccole cellule, Diseases [C] - Cancer [C04]
 
 
IMspire150, NCT02908672 / 2016-002482-54: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Checkmark Data from IMspire150 trial in combination with Cotellic and Zelboraf for 1L melanoma
Nov 2020 - Nov 2020: Data from IMspire150 trial in combination with Cotellic and Zelboraf for 1L melanoma
Checkmark Data from IMspire150 trial in combination with Cotellic and Zelboraf for BRAF V600+ melanoma at AACR 2020
Jun 2020 - Jun 2020: Data from IMspire150 trial in combination with Cotellic and Zelboraf for BRAF V600+ melanoma at AACR 2020
Checkmark From IMspire150 trial in combination with Cotellic and Zelboraf for 1L melanoma
More
Active, not recruiting
3
514
Europe, Canada, US, RoW
Atezolizumab, Atezolizumab Placebo, Cobimetinib, Vemurafenib, Vemurafenib Placebo
Hoffmann-La Roche
Melanoma
10/19
07/24
2019-002784-10: Study in patients with untreated extensive-stage small cell lung cancer with carboplatin or cisplatin plus etoposide with Atezolizumab Estudio para pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado con carboplatino o cisplatino más etopósido con Atezolizumab

Ongoing
3
150
Europe
Atezolizumab, RO5541267/F03, Concentrate for solution for infusion, Tecentriq.
Roche Farma S.A. (Soc. Unipersonal), Roche Farma S.A. (Soc. Unipersonal)
First-line treatment for extensive-stage small cell lung cancer Primera línea de tratamiento en pacientes con Cáncer de pulmón microcítico en etapa avanzada, Untreated extensive-stage small cell lung cancer Cáncer de pulmón de célula pequeña en etapa avanzada no tratado, Diseases [C] - Cancer [C04]
 
 
IMpassion131, NCT03125902 / 2016-004024-29: A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Checkmark Data from Impassion131 trial in combination with paclitaxel for 1L TNBC at ESMO 2020
Sep 2020 - Sep 2020: Data from Impassion131 trial in combination with paclitaxel for 1L TNBC at ESMO 2020
Checkmark From IMpassion 131 trial in combination with paclitaxel for 1L TNBC
Aug 2020 - Aug 2020: From IMpassion 131 trial in combination with paclitaxel for 1L TNBC
Checkmark Data from P3 IMpassion131 trial in mTNBC
More
Completed
3
653
Europe, Canada, Japan, US, RoW
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, MPDL3280A, TECENTRIQ, Atezolizumab Placebo, Paclitaxel
Hoffmann-La Roche
Triple-Negative Breast Cancer
11/19
01/23
2020-001973-66: STUDY TO EVALUATE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA NOT PREVIOUSLY TREATED WITH SYSTEMIC THERAPY STUDIO PER VALUTARE LA SICUREZZA E L’EFFICACIA DI ATEZOLIZUMAB IN ASSOCIAZIONE A BEVACIZUMAB IN PAZIENTI AFFETTI DA CARCINOMA EPATOCELLULARE NON OPERABILE, NON PRECEDENTEMENTE TRATTATO CON TERAPIA SISTEMICA

Not yet recruiting
3
150
Europe
Atezolizumab, Bevacizumab, [RO5541267], [-], Concentrate for solution for infusion, Tecentriq, Avastin
ROCHE SPA, Roche SpA
Unresectable hepatocellular carcinoma (HCC) Carcinoma epatocellulare (HCC) non resecabile, Unresectable hepatocellular carcinoma (HCC) Carcinoma epatocellulare (HCC) non resecabile, Diseases [C] - Cancer [C04]
 
 
IMpassion050, NCT03726879 / 2018-001881-40: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Hourglass Jan 2021 - Dec 2021 : From Impassion050 trial in combination with doxorubicin, cyclophosphamide followed by paclitaxel, trastuzumab and pertuzumab in early HER2+ breast cancer
Checkmark From IMpassion050 trial for neoadjuvant HER2-positive breast cancer
Jun 2021 - Jun 2021: From IMpassion050 trial for neoadjuvant HER2-positive breast cancer
Completed
3
454
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Placebo, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Neosar, Paclitaxel, Taxol, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Trastuzumab Emtansine, Kadcyla
Hoffmann-La Roche, Chugai Pharmaceutical
Breast Cancer
02/21
08/23
2020-004210-35: A randomised, multicenter, open label phase IIIb study, in which patients with intermediate-stagehepatocellular carcinoma will be treated either with Atezolizumab plus Bevacizumab or with transarterial Chemoembolization (TACE). Eine randomisierte, multizentrische, unverblindete Phase IIIb Studie, in der Patienten mit Hepatozellulärem Karzinom im intermediären Stadium entweder mit Atezolizumab plus Bevacizumab oder mit transarterieller Chemoembolisation (TACE) behandelt werden.

Ongoing
3
434
Europe
Atezolizumab, Bevacizumab, RO5541267, RO4876646, Concentrate for solution for infusion, TECENTRIQ 1200 mg, AVASTIN
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, F. Hoffmann-La Roche Ltd
intermediate-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, Diseases [C] - Cancer [C04]
 
 
COSMIC-312, NCT03755791 / 2018-003354-24: Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

Hourglass Jul 2022 - Dec 2022 : Market entry in combination with Tecentriq for 1L liver cancer (based on COSMIC-312 trial)
Checkmark Final data from COSMIC-312 trial in combination with Tecentriq for 1L HCC
Mar 2022 - Mar 2022: Final data from COSMIC-312 trial in combination with Tecentriq for 1L HCC
Checkmark Presentation of data from COSMIC-312 trial in combination with Tecentriq for 1L HCC at ESMO Asia 2021
Nov 2021 - Nov 2021: Presentation of data from COSMIC-312 trial in combination with Tecentriq for 1L HCC at ESMO Asia 2021
More
Active, not recruiting
3
837
Europe, Canada, US, RoW
Cabozantinib, XL184, Cabometyx®, Sorafenib, Nexavar®, Atezolizumab, Tecentriq®
Exelixis
Hepatocellular Carcinoma
03/21
12/24
2021-000615-23: Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with metastatic cancer in response after 6 months of standard IO

Not yet recruiting
3
646
Europe
pembrolizumab, durvalumab, atezolizumab, avelumab, bevacizumab, pemetrexed, cabozantinib, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Film-coated tablet, OPDIVO, KEYTRUDA, IMFINZI, Tecentriq, Bavencio
UNICANCER, PHRC-K 2020, Fondation BMS
Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K and melanoma, or hepatocellular carcinoma) in PR or CR (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI)., -, Diseases [C] - Cancer [C04]
 
 
NCT05055908: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Recruiting
3
12000
RoW
Pemetrexed plus Pembrolizumab, Bevacizumab, Pembrolizumab, Pemetrexed
Hunan Province Tumor Hospital
Lung Cancer
07/25
09/27
ATALANTE, NCT02891824 / 2015-005471-24: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Checkmark Presentation of data from ATALANTE trial for 3L ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from ATALANTE trial for 3L ovarian cancer at ESMO 2022
Active, not recruiting
3
614
Europe, RoW
atezolizumab + avastin + platinum-based chemotherapy, Tecentriq, placebo + avastin + platinum-based chemotherapy
ARCAGY/ GINECO GROUP, Hoffmann-La Roche
Ovarian Cancer
10/21
09/24
2021-005034-42: Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC)

Ongoing
3
450
Europe
MK-7684A, Atezolizumab, [-], Solution for infusion, Concentrate for solution for infusion, TECENTRIQ®
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Extensive-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Diseases [C] - Cancer [C04]
 
 
IMscin001, NCT03735121 / 2018-002328-18: A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Checkmark Data from IMscin001 trial for NSCLC at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from IMscin001 trial for NSCLC at ESMO-IO 2022
Checkmark Results from IMscin001 trial for NSCLC
Aug 2022 - Aug 2022: Results from IMscin001 trial for NSCLC
Active, not recruiting
3
438
Europe, RoW
Atezolizumab, Tecentriq, rHuPH20, ENHANZE
Hoffmann-La Roche
Non-Small Cell Lung Cancer
04/22
12/24
IPSOS, NCT03191786 / 2015-004105-16: A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Checkmark Presentation of data from IPSOS trial for Platinum-Ineligible NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from IPSOS trial for Platinum-Ineligible NSCLC at ESMO 2022
Completed
3
453
Europe, Canada, RoW
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, MPDL3280A, Vinorelbine, Navelbine®, Gemcitabine, Gemzar®
Hoffmann-La Roche
Non-Small Cell Lung Cancer
04/22
10/23
IMvigor130, NCT02807636 / 2016-000250-35: Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Checkmark From IMvigor130 trial in 1L urothelial cancer
Sep 2019 - Sep 2019: From IMvigor130 trial in 1L urothelial cancer
Completed
3
1213
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Carboplatin, Gemcitabine, Placebo, Cisplatin
Hoffmann-La Roche
Urothelial Carcinoma
08/22
02/24
SKYSCRAPER-02, NCT04256421 / 2019-003301-97: A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From SKYSCRAPER-02 trial in combination with or without tiragolumab for ES SCLC
Mar 2022 - Mar 2022: From SKYSCRAPER-02 trial in combination with or without tiragolumab for ES SCLC
Active, not recruiting
3
490
Europe, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Carboplatin, Etoposide, Placebo
Hoffmann-La Roche
Small Cell Lung Cancer
09/22
04/26
CONTACT-01, NCT04471428 / 2020-000100-11: Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Checkmark CONTACT-01 study in combination with Tecentriq for 2L NSCLC did not meet its primary endpoint of overall survival at the final analysis
Dec 2022 - Dec 2022: CONTACT-01 study in combination with Tecentriq for 2L NSCLC did not meet its primary endpoint of overall survival at the final analysis
Active, not recruiting
3
366
Europe, Japan, US, RoW
Cabozantinib, Atezolizumab, Tecentriq, Docetaxel
Hoffmann-La Roche, Exelixis
Carcinoma, Non-Small-Cell Lung
09/22
10/24
2021-003243-21: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Estudio de XL092 + Atezolizumab frente a Regorafenib en pacientes con cáncer colorrectal metastásico (STELLAR-303)

Not yet recruiting
3
600
Europe
XL092, Atezolizumab, Regorafenib, XL092, RO5541267, Film-coated tablet, Concentrate for solution for infusion, TECENTRIQ, Stivarga
Exelixis, Inc., Exelixis, Inc.
Metastatic colorectal cancer (CRC) Cáncer colorrectal metastásico, Colorectal cancer Cáncer colorrectal, Diseases [C] - Cancer [C04]
 
 
IMbrave050, NCT04102098 / 2019-002491-14: A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Checkmark Data from IMbrave050 trial in combination with Tecentriq for adjuvant HCC
Jan 2023 - Jan 2023: Data from IMbrave050 trial in combination with Tecentriq for adjuvant HCC
Checkmark Data from IMbrave050 trial in combination with Avastin for adjuvant HCC
Jan 2023 - Jan 2023: Data from IMbrave050 trial in combination with Avastin for adjuvant HCC
Active, not recruiting
3
668
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Hoffmann-La Roche
Carcinoma, Hepatocellular
10/22
07/27
IMbassador250, NCT03016312 / 2016-003092-22: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Completed
3
772
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq®, Enzalutamide, Xtandi®
Hoffmann-La Roche
Prostatic Neoplasms, Castration-Resistant
12/22
12/22
CONTACT-03, NCT04338269 / 2020-000502-29: A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Jan 2023 - Jun 2023: Top-line data readout from CONTACT-03 trial in combination with Tecentriq for advanced or metastatic RCC
Checkmark Enrollment is complete for CONTACT-03 study in combination with Tecentriq for locally advanced/metastatic clear cell/non-clear cell (papillary or unclassified only) 1L RCC
Jan 2022 - Jan 2022: Enrollment is complete for CONTACT-03 study in combination with Tecentriq for locally advanced/metastatic clear cell/non-clear cell (papillary or unclassified only) 1L RCC
Checkmark CONTACT-03 phase 3 pivotal trial initiation in combination with Tecentriq for 2L RCC
Jul 2020 - Jul 2020: CONTACT-03 phase 3 pivotal trial initiation in combination with Tecentriq for 2L RCC
Active, not recruiting
3
522
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Cabozantinib, Cabometyx
Hoffmann-La Roche, Exelixis, Chugai
Carcinoma, Renal Cell
01/23
06/24
IMpower151, NCT04194203: A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting
3
305
RoW
Atezolizumab, Tecentriq, Placebo, Bevacizumab, Avastin, Paclitaxel, Pemetrexed, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
02/23
06/24
SKYSCRAPER-08, NCT04540211: A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Jan 2023 - Dec 2023: Data from SKYSCRAPER-08 trial in combination with tiragolumab for metastatic esophageal carcinoma
Active, not recruiting
3
461
RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Paclitaxel, Cisplatin, Atezolizumab Matching Placebo, Tiragolumab Matching Placebo
Hoffmann-La Roche
Esophageal Cancer
02/23
08/25
IPATunity170, NCT04177108 / 2019-000810-12: A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Calendar Oct 2025 - Dec 2025: From trial in combination with Tecentriq for advanced TNBC
Calendar Oct 2025 - Dec 2025: From trial in combination with Ipatasertib for advanced TNBC
Completed
3
242
Europe, Canada, Japan, US, RoW
Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib
Hoffmann-La Roche
Triple-Negative Breast Cancer
02/23
02/23
ATTLAS, NCT03991403: Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Active, not recruiting
3
228
RoW
Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab, Carboplatin, Paclitaxel, Carboplatin or cisplatin
Samsung Medical Center
Non-small Cell Lung Cancer
03/23
03/24
2022-003157-55: Clinical study on the efficacy and safety of Tumor Treating Fields, atezolizumab, gemcitabine and nab-paclitaxel as first line treatment for metastatic pancreatic carcinoma.

Ongoing
3
76
Europe
Concentrate for solution for injection/infusion, Tecentriq 840 mg concentrate for solution for infusion
Novocure GmbH, Novocure GmbH
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Metasztatikus duktális hasnyálmirigy-adenokarcinóma (mPDAC), Pancreatic Cancer Hasnyálmirigyrák, Diseases [C] - Cancer [C04]
 
 
NeoTRIPaPDL1, NCT02620280 / 2014-005017-23: Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Completed
3
278
Europe, RoW
Carboplatin, Carboplatin Teva, Abraxane, nab-paclitaxel, MPDL3280A, Atezolizumab, Surgery, Anthra
Fondazione Michelangelo
Invasive Ductal Breast Carcinoma
01/24
01/24
CONTACT-2, NCT04446117 / 2020-000348-77: Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Hourglass Feb 2024 - Mar 2024 : FY'23 - Submission in Japan for CRPC (based on CONTACT-02 study)
Jan 2023 - Dec 2023: From CONTACT-02 trial in combination with Cabometyx for metastatic CRPC
Jan 2023 - Dec 2023: From trial in combination with Tecentriq for mCRPC
Hourglass Jan 2023 - Jun 2023 : Completion of enrollment of P3 CONTACT-02 trial in combination with Tecentriq for metastatic CRPC
Active, not recruiting
3
575
Europe, Canada, Japan, US, RoW
Cabozantinib, XL184, Cabometyx®, Atezolizumab, Tecentriq®, Abiraterone Acetate, Abiraterone, Zytiga, Enzalutamide, Xtandi, Prednisone
Exelixis, Roche-Genentech, Takeda
Metastatic Prostate Cancer, Prostate Adenocarcinoma
06/23
08/24
MAURIS, NCT04028050: A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Completed
3
155
Europe
Atezolizumab, MPDL3280A, RO5541267, Tecentriq, Carboplatin, Etoposide
Hoffmann-La Roche
Small Cell Lung Carcinoma
07/23
07/23
IMpassion030, NCT03498716 / 2016-003695-47: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Jan 2023 - Dec 2023: Data from IMpassion030 trial for operable TNBC
Checkmark First patient in P3 IMpassion030 trial for TNBC
May 2018 - May 2018: First patient in P3 IMpassion030 trial for TNBC
Completed
3
2203
Europe, Japan, US, RoW
Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide
Hoffmann-La Roche, Breast International Group, Alliance Foundation Trials (AFT), Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU), Frontier Science & Technology Research Foundation, Inc.
Triple Negative Breast Cancer
08/23
08/23
SKYSCAPPER-02C, NCT04665856: Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Active, not recruiting
3
123
RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Carboplatin, Etoposide, Tiragolumab Matching Placebo
Hoffmann-La Roche
Small Cell Lung Carcinoma
08/23
04/25
AtTEnd, NCT03603184 / 2018-001072-37 / ACTRN12619000900112: Atezolizumab Trial in Endometrial Cancer -

Active, not recruiting
3
550
Europe, Japan, RoW
Atezolizumab, Tecentriq, Placebos, Paclitaxel, Carboplatin
Mario Negri Institute for Pharmacological Research, Hoffmann-La Roche
Endometrial Cancer
01/25
05/25
OLIGAMI, NCT06135714: Metastasis-directed Therapy for Oligometastases of Breast Cancer

Recruiting
3
340
Japan
Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery, Same systemic therapy after secondary registration
Tokyo Medical and Dental University
Breast Cancer, Oligometastasis, Metastatic Breast Cancer
11/26
10/32
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
12/24
12/26
ABC-HCC, NCT04803994 / 2020-004210-35: The Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Recruiting
3
434
Europe, Japan
Atezolizumab, Tecentriq, Bevacizumab, Avastin, TACE, transarterial chemoembolization
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, F. Hoffmann-La Roche Ltd
Hepatocellular Carcinoma
04/25
04/25
GeparDouze, NCT03281954 / 2017-002771-25: Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Jan 2023 - Dec 2023: Data from trial in combination with carboplatin and nab-paclitaxel for TNBC
Active, not recruiting
3
1550
Canada, US
Placebo, Atezolizumab
NSABP Foundation Inc, Genentech, Inc., Hoffmann-La Roche
Triple Negative Breast Cancer
12/24
11/27
KATE3, NCT04740918 / 2020-002818-41: A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Active, not recruiting
3
96
Europe, Canada, US, RoW
Trastuzumab Emtansine, Kadcyla, T-DM1, RO5304020, Atezolizumab, Tecentriq, RO5541267, MPDL3280A, Placebo
Hoffmann-La Roche
Metastatic Breast Cancer
04/24
04/24
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
12/23
12/23
AGO-OVAR 2.29, NCT03353831 / 2017-000202-37: Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Active, not recruiting
3
550
Europe
Bevacizumab, Atezolizumab, Chemotherapy, Placebos
AGO Research GmbH, Hoffmann-La Roche
Recurrent Ovarian Carcinoma
01/24
12/24
ANITA, NCT03598270 / 2018-000366-11: Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Active, not recruiting
3
414
Europe
Placebo, Placebo of Atezolizumab, Carboplatin, Paclitaxel, Niraparib, Gemcitabine, Pegylated liposomal doxorubicin (PLD), Atezolizumab, Tecentriq
Grupo Español de Investigación en Cáncer de Ovario, Hoffmann-La Roche, GlaxoSmithKline, AGO Study Group, Belgian Gynaecological Oncology Group, ARCAGY/ GINECO GROUP, Israeli Society of Gynecologic Oncology, MaNGO, Apices Soluciones S.L.
Recurrent Ovarian Carcinoma
01/24
01/24
BEAT-meso, NCT03762018 / 2018-002180-25: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Active, not recruiting
3
401
Europe
Carboplatin, Carboplatin Accord, Pemetrexed, Alimta, Bevacizumab, Avastin, Atezolizumab, Tecentriq, RO5541267
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Pleural Mesothelioma Malignant Advanced
06/24
06/24
BEATcc, NCT03556839 / 2018-000367-83: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Active, not recruiting
3
404
Europe, Japan, US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Cisplatin/Carboplatin, Paclitaxel
Grupo Español de Investigación en Cáncer de Ovario, Hoffmann-La Roche, ARCAGY/ GINECO GROUP, Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies, MaNGO, NSGO, Japanese Gynecologic Oncology Group, Gynecologic Oncology Group Foundation, AGO Study Group, Apices Soluciones S.L.
Carcinoma of the Cervix, Stage IVB
11/24
11/24
SKYSCRAPER-15, NCT06267001: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Recruiting
3
1150
Europe, Japan, US, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, MTIG7192A; RO7092284, Placebo
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
03/34
06/39
AMETHISTA, NCT04487067: A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Active, not recruiting
3
152
Europe
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Hoffmann-La Roche
Carcinoma, Hepatocellular
08/24
08/24
ALBAN, NCT03799835 / 2017-004512-19: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Active, not recruiting
3
516
Europe
BCG, Bacillus Calmette Guerin (BCG) Medac®, OncoTice, Atezolizumab, MPDL3280A, Tecentriq®
UNICANCER, Hoffmann-La Roche
Bladder Cancer
04/24
02/28
NCT02912559: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Active, not recruiting
3
700
Europe, US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
04/25
04/25
NCT04732286: A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

Completed
3
100
Europe
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Hoffmann-La Roche
Carcinoma, Hepatocellular
04/24
04/24
NRG-BR004, NCT03199885: Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Active, not recruiting
3
190
Canada, US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trazimera
National Cancer Institute (NCI), NRG Oncology
Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
04/24
05/25
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
10/24
12/25
IMpassion132, NCT03371017 / 2016-005119-42: A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

Hourglass Jan 2023 - Dec 2023 : Results from IMpassion132 study for 1L PD-L1+ TNBC
Active, not recruiting
3
572
Europe, US, RoW
Atezolizumab, Placebo, Gemcitabine, Capecitabine, Carboplatin
Hoffmann-La Roche
Triple Negative Breast Neoplasms
06/24
06/24
IMpower010, NCT02486718 / 2014-003205-15: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer []

Checkmark Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Aug 2022 - Aug 2022: Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Checkmark Data from IMpower010 trial for stage IB-IIIA NSCLC
Aug 2022 - Aug 2022: Data from IMpower010 trial for stage IB-IIIA NSCLC
Checkmark Approval for adjuvant NSCLC based on IMpower010
More
Active, not recruiting
3
1280
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A; TECENTRIQ, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
Hoffmann-La Roche
Non-Small Cell Lung Cancer
01/24
08/35
IMbrave251, NCT04770896 / 2020-005231-78: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Active, not recruiting
3
554
Europe, Canada, Japan, RoW
Atezolizumab, Tecentriq, Lenvatinib, Sorafenib
Hoffmann-La Roche
Unresectable Hepatocellular Carcinoma
07/25
07/25
SKYSCRAPER-03, NCT04513925 / 2019-004773-29: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Calendar Jan 2025 - Dec 2025: From SKYSCRAPER-03 trial in combination with Tecentriq for unresectable stage 3 NSCLC
Active, not recruiting
3
829
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, MTIG7192A; RO7092284, Durvalumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
10/24
12/27
COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting
3
120
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
11/24
11/24
EL1SSAR, NCT04148911 / 2019-002488-91: A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Active, not recruiting
3
184
Europe, RoW
Atezolizumab, Tecentriq, Nab-Paclitaxel, Abraxane
Hoffmann-La Roche
Triple-Negative Breast Cancer
12/24
12/24
IMpower030, NCT03456063 / 2017-002857-12: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data from IMpower030 trial for neoadjuvant NSCLC
Hourglass Jan 2022 - Dec 2022 : EFS data from P3 IMpower030 trial for resectable stage II, IIIA, or select IIIB NSCLC
Active, not recruiting
3
453
Europe, Japan, US, RoW
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Tecentriq, Placebo Comparator, Nab-paclitaxel, Abraxane, Pemetrexed, Alimta, Carboplatin, Cisplatin, Gemcitabine, Gemzar
Hoffmann-La Roche
Non-Small-Cell Lung
01/25
01/25
SKYSCRAPER-01, NCT04294810 / 2019-002925-31: A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Jul 2023 - Sep 2023: Final analysis data from SKYSCRAPER-01 trial in combination with tiragolumab for NSCLC
Jan 2023 - Feb 2023: Interim data from SKYSCRAPER-01 trial in combination with tiragolumab for NSCLC
Checkmark Interim results from SKYSCRAPER-01 trial in combination with Tecentriq for 1L NSCLC
Jul 2022 - May 2022: Interim results from SKYSCRAPER-01 trial in combination with Tecentriq for 1L NSCLC
Active, not recruiting
3
620
Europe, Japan, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Matching Placebo
Hoffmann-La Roche
Non-Small Cell Lung Cancer
02/25
02/25
IMvigor011, NCT04660344 / 2020-004418-36: A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Placebo
Hoffmann-La Roche
Muscle-invasive Bladder Cancer
03/25
04/31
IMforte, NCT05091567 / 2021-001930-20: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

Active, not recruiting
3
690
Europe, US, RoW
Atezolizumab, Tecentriq, RO5541267, Lurbinectedin, PM01183/JZP712, Carboplatin, Etoposide
Hoffmann-La Roche, Jazz Pharmaceuticals
Small-Cell Lung Cancer
04/25
03/26
KeyVibe-008, NCT05224141 / 2021-005034-42: Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Active, not recruiting
3
450
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Saline placebo, Etoposide, Cisplatin, PLATINOL-AQ®, Atezolizumab, TECENTRIQ®, Carboplatin, PARAPLATIN®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Small Cell Lung Carcinoma
05/25
06/27
AMBITION, NCT04732598: A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Active, not recruiting
3
280
Japan
Paclitaxel + bevacizumab therapy, Paclitaxel + bevacizumab + atezolizumab
Japanese Foundation for Cancer Research, Chugai Pharmaceutical
Breast Cancer
09/25
09/25
STELLAR-303, NCT05425940: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Recruiting
3
874
Europe, US, RoW
XL092, Atezolizumab, Tecentriq®, Regorafenib, Stivarga®
Exelixis
Colorectal Cancer
08/25
02/26
NCT05112965: An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Recruiting
3
100
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Pemetrexed, Paclitaxel, Enzalutamide, Xtandi
Hoffmann-La Roche
Neoplasms
12/25
12/25
NCT06031597: Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Not yet recruiting
3
105
NA
radiotherapy, Platinum-Based Drug, Cisplatin, Immunotherapy, Nivolumab, Atezolizumab, Durvalumab, Pembrolizumab, Tislelizumab, Sugemalimab, Sintilimab, Camrelizumab, Immunotherapeutic Agent
Zhejiang Cancer Hospital
Non-small Cell Lung Cancer Stage III
12/25
12/25
IMvoke010, NCT03452137 / 2017-003302-40: A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Jan 2023 - Dec 2023: Data from IMvoke010 trial in combination with chemotherapy for adjuvant SCCHN
Terminated
3
406
Europe, Canada, Japan, US, RoW
Atezolizumab, Placebo
Hoffmann-La Roche
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
09/23
03/24
Astefania, NCT04873362 / 2020-003681-40: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Recruiting
3
1150
Europe, US, RoW
Atezolizumab, Tecentriq, RO5541267, MPDL3280A, Trastuzumab Emtansine, Kadcyla, T-DM1, RO5304020, Placebo, Trastuzumab, Herceptin
Hoffmann-La Roche
Breast Cancer
08/28
10/34
NCT04637594: Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Active, not recruiting
3
3
US
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
07/26
09/30
Imbrave 152, NCT05904886: A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Tiragolumab, MTIG7192A, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Carcinoma, Hepatocellular
09/26
09/26
NCT04157985: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Recruiting
3
578
US
Continue PD-1/PD-L1 Inhibitors treatment, Keytruda (pembrolizumab), Optiva (nivolumab), Tecentriq (atezolizumab), Yervoy (ipilimumab), LIBTAYO (cemiplimab), Discontinue PD-1/PD-L1-1 inhibitor
Jason J. Luke, MD
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
10/28
10/28
MRD-GI, NCT05482516: Evaluating Novel Therapies in ctDNA Positive GI Cancers

Recruiting
3
20
US
Atezolizumab, TECENTRIQ, Bevacizumab, Avastin
Georgetown University, Genentech, Inc., Natera, Inc.
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
12/26
12/28
APTneo, NCT03595592 / 2017-000981-31: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Active, not recruiting
3
650
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Carboplatin, Carboplatin Hospiria, Paclitaxel, Paclitaxel Hospiria, Doxorubicin, Doxorubicin Pfizer, Cyclophosphamide, Cyclophosphamide Sandoz, Atezolizumab, Tecentriq, Surgery
Fondazione Michelangelo, Hoffmann-La Roche
Invasive Breast Cancer
12/26
03/27
NRG-LU005, NCT03811002: Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Active, not recruiting
3
545
Japan, US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
12/26
12/26
SKYSCRAPER-07, NCT04543617 / 2020-001178-31: A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Active, not recruiting
3
760
Europe, Japan, US, RoW
Tiragolumab, MTIG7192A, RO7092284, Atezolizumab, Tecentriq, RO5541267, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo
Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
03/27
03/27
NCT05047250: A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Recruiting
3
60
RoW
Atezolizumab, Tecentriq
Hoffmann-La Roche
Non-Small Cell Lung Cancer
02/27
08/27
SHIELD-RT, NCT03775265: Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Active, not recruiting
3
475
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy of Bladder, Bladder Biopsy, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cystoscopy, CS, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mitomycin, Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Survey Administration, Transurethral Resection of Bladder Tumor, Transurethral resection (TURBT), TURBT
National Cancer Institute (NCI)
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
06/27
06/27
NCT04214262: Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Recruiting
3
480
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
05/28
05/28
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
NCT05984511: TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Not yet recruiting
3
234
NA
I-125 Seeds Brachytherapy in PVTT, Iodine-125 Seeds Implantation, Transcatheter arterial chemoembolization, TACE, Atezolizumab plus Bevacizumab, atezolizumab-bevacizumab; Atez/Bev treatment
Third Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Fifth Affiliated Hospital, Sun Yat-Sen University, Second Affiliated Hospital of Guangzhou Medical University, Maoming People's Hospital, Shandong Provincial Third Hospital
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
08/28
08/29
TALENTACE, NCT04712643: A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Active, not recruiting
3
342
Japan, RoW
Atezolizumab, Tecentriq, Becavizumab, Avastin, Transarterial chemoembolization (TACE)
Hoffmann-La Roche
Hepatocellular Carcinoma
02/29
02/29
IMbrella A, NCT03148418 / 2016-005189-75: A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study

Active, not recruiting
3
382
Europe, Canada, Japan, US, RoW
Atezolizumab, RO5541267, Tecentriq, Bevacizumab, Avastin
Hoffmann-La Roche
Cancer
03/30
03/30
UmbrellaMAX, NCT05862285: A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Recruiting
3
60
Europe, Japan, RoW
Ipatasertib, RO5532961, Tiragolumab, RO7092284, Atezolizumab, RO5541276
Hoffmann-La Roche
Cancer
03/33
03/33
NCT05809336: Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Completed
2/3
172
RoW
Inosine 0.2g orally 3 times/day, Camrelizumab for injection, Sintilimab injection, Penpulimab injection, Tislelizumab injection, Pembrolizumab injection, Toripalimab, Atezolizumab, chemotherapy/targeting, PD-1/PD-L1 inhibitor ,chemotherapy/targeting
Beijing Friendship Hospital
Advanced Solid Tumor
10/22
10/22
NRG-GY009, NCT02839707: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
2/3
443
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
05/23
09/24
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, GDC-6036, RO7435846, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
FFCD 2101-PRODIGE 81, NCT05665348: Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Not yet recruiting
2/3
574
Europe
Ipilimumab Injection, Atezolizumab, Bevacizumab, Atezolizumab Injection
Federation Francophone de Cancerologie Digestive
HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
09/24
04/26
SWOG S2012, NCT05058651: Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Recruiting
2/3
189
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting
National Cancer Institute (NCI)
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
10/28
10/28
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Recruiting
2/3
445
RoW
PM8002, Platinum, Atezolizumab, Etoposide
Biotheus Inc.
SCLC
06/25
12/25
NCT01810913: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Recruiting
2/3
613
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cetuximab, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
01/27
01/27
 

Download Options